Related references
Note: Only part of the references are listed.A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine
Tiffini Voss et al.
CEPHALALGIA (2016)
Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial
Hong Sun et al.
LANCET NEUROLOGY (2016)
Chronic migraine headache prevention with noninvasive vagus nerve stimulation The EVENT study
Stephen D. Silberstein et al.
NEUROLOGY (2016)
Metabotropic glutamate receptor 5: a target for migraine therapy
Maggie W. Waung et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2016)
Putting migraine to sleep: Rexants as a preventive strategy
Peter J. Goadsby
CEPHALALGIA (2015)
Glial Attenuation With Ibudilast in the Treatment of Medication Overuse Headache: A Double-Blind, Randomized, Placebo-Controlled Pilot Trial of Efficacy and Safety
Jacinta L. Johnson et al.
HEADACHE (2015)
Single-pulse transcranial magnetic stimulation (sTMS) for the acute treatment of migraine: evaluation of outcome data for the UK post market pilot program
Ria Bhola et al.
JOURNAL OF HEADACHE AND PAIN (2015)
Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013
Theo Vos et al.
LANCET (2015)
Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
Marcelo E. Bigal et al.
LANCET NEUROLOGY (2015)
Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
Marcelo E. Bigal et al.
LANCET NEUROLOGY (2015)
Incedible progress for an era of better migraine care
Peter J. Goadsby
NATURE REVIEWS NEUROLOGY (2015)
Evidence for orexinergic mechanisms in migraine
Jan Hoffmann et al.
NEUROBIOLOGY OF DISEASE (2015)
Neuronal PAC1 receptors mediate delayed activation and sensitization of trigeminocervical neurons: Relevance to migraine
Simon Akerman et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis
Almira Chabi et al.
CEPHALALGIA (2015)
A second trigeminal CGRP receptor: function and expression of the AMY1 receptor
Christopher S. Walker et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2015)
Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38
Faisal Mohammad Amin et al.
BRAIN (2014)
Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks
Baltazar Gomez-Mancilla et al.
CEPHALALGIA (2014)
A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study
Lars J. Stovner et al.
CEPHALALGIA (2014)
Effect of noninvasive vagus nerve stimulation on acute migraine: An open-label pilot study
P. J. Goadsby et al.
CEPHALALGIA (2014)
Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study
David W. Dodick et al.
LANCET NEUROLOGY (2014)
Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial
David W. Dodick et al.
LANCET NEUROLOGY (2014)
Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention
Tony W. Ho et al.
NEUROLOGY (2014)
Pituitary adenylate cyclase activating polypeptide and migraine
Alessandro S. Zagami et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2014)
A randomized controlled trial of intranasal ketamine in migraine with prolonged aura
Shazia K. Afridi et al.
NEUROLOGY (2013)
Migraine prevention with a supraorbital transcutaneous stimulator A randomized controlled trial
Jean Schoenen et al.
NEUROLOGY (2013)
The nitric oxide synthase inhibitor and serotonin-receptor agonist NXN-188 during the aura phase of migraine with aura: A randomized, double-blind, placebo-controlled cross-over study
Anders Hougaard et al.
SCANDINAVIAN JOURNAL OF PAIN (2013)
Acid-sensing ion channel 1: A novel therapeutic target for migraine with aura
Philip R. Holland et al.
ANNALS OF NEUROLOGY (2012)
Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: Results from a randomized, multicenter, double-blinded, controlled study
Stephen D. Silberstein et al.
CEPHALALGIA (2012)
The economic cost of brain disorders in Europe
J. Olesen et al.
EUROPEAN JOURNAL OF NEUROLOGY (2012)
Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study
Markus Farkkila et al.
LANCET NEUROLOGY (2012)
BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: Results from a phase II study
Hans-Christoph Diener et al.
CEPHALALGIA (2011)
Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study
Joel R. Saper et al.
CEPHALALGIA (2011)
Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine
David J. Hewitt et al.
CEPHALALGIA (2011)
Diencephalic and brainstem mechanisms in migraine
Simon Akerman et al.
NATURE REVIEWS NEUROSCIENCE (2011)
Preclinical pharmacological profile of the selective 5-HTIF receptor agonist lasmiditan
David L. Nelson et al.
CEPHALALGIA (2010)
Acute treatment of migraine with the selective 5-HTIF receptor agonist lasmiditan - A randomised proof-of-concept trial
Michel D. Ferrari et al.
CEPHALALGIA (2010)
OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double-Blind, Randomized, Placebo-Controlled Phases of the PREEMPT Clinical Program
David W. Dodick et al.
HEADACHE (2010)
Current practice and future directions in the prevention and acute management of migraine
Peter J. Goadsby et al.
LANCET NEUROLOGY (2010)
Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial
Richard B. Lipton et al.
LANCET NEUROLOGY (2010)
CGRP and its receptors provide new insights into migraine pathophysiology
Tony W. Ho et al.
NATURE REVIEWS NEUROLOGY (2010)
Telmisartan in migraine prophylaxis: a randomized, placebo-controlled trial
H. C. Diener et al.
CEPHALALGIA (2009)
Investigation of the role of mGluR5 inhibition in migraine: a proof of concept study of ADX10059 in acute treatment of migraine
P. J. Goadsby et al.
CEPHALALGIA (2009)
702 A RANDOMISED, TWO-PERIOD CROSS-OVER STUDY TO INVESTIGATE THE EFFICACY OF THE TRPV1 ANTAGONIST SB-705498 IN ACUTE MIGRAINE
B. Chizh et al.
EUROPEAN JOURNAL OF PAIN (2009)
Effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study
Anne W. Hauge et al.
LANCET NEUROLOGY (2009)
Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial
Tony W. Ho et al.
LANCET (2008)
Treatment-emergent CNS symptoms following triptan therapy are part of the attack
P. J. Goadsby et al.
CEPHALALGIA (2007)
Modulation of nociceptive dural input to the trigeminal nucleus caudalis via activation of the orexin 1 receptor in the rat
P. R. Holland et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2006)
Consensus statement:: Cardiovascular safety profile of triptans (5-HT1B/1D agonists) in the acute treatment of migraine
D Dodick et al.
HEADACHE (2004)
Topiramate in migraine prevention - Results of a large controlled trial
SD Silberstein et al.
ARCHIVES OF NEUROLOGY (2004)
Calcitonin gene-related peptide receptor antagonist BIBN4096BS for the acute treatment of migraine
J Olesen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Topiramate for migraine prevention - A randomized controlled trial
JL Brandes et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine
CN Sang et al.
CEPHALALGIA (2004)
Differential modulation of nociceptive dural input to [hypocretin] orexin A and B receptor activation in the posterior hypothalamic area
T Bartsch et al.
PAIN (2004)
RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks
HC Diener
CEPHALALGIA (2003)
Evidence for serotonin (5-HT)(1B), 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input
PJ Goadsby et al.
NEUROSCIENCE (2003)
Prophylactic treatment of migraine with an angiotensin II receptor blocker - A randomized controlled trial
E Tronvik et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels
S Akerman et al.
BRITISH JOURNAL OF PHARMACOLOGY (2002)
Drug therapy: Migraine - Current understanding and treatment.
PJ Goadsby et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Selective seratonin 1F (5-HT1F) receptor agonist LY334370 for acute migraine:: a randomised controlled trial
DJ Goldstein et al.
LANCET (2001)
Lanepitant, an NK-1 antagonist, in migraine prevention
DJ Goldstein et al.
CEPHALALGIA (2001)
Pharmacological treatment of the ion transport defect in cystic fibrosis
GM Roomans
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2001)
No contractile effect for 5-HT1D and 5-HT1F receptor agonists in human and bovine cerebral arteries:: similarity with human coronary artery
I Bouchelet et al.
BRITISH JOURNAL OF PHARMACOLOGY (2000)
Share Paper
